Last month marked a great beginning to 2026 for Novartis in Saudi Arabia, with the company receiving two major recognitions that underscore its leadership in clinical research and its contribution to the Kingdom’s evolving healthcare ecosystem.
At the “Clinical Trials Transformation Conference: Unraveling the Future” held in Riyadh, Novartis was awarded first place in the Clinical Research Contribution Award. Presented by King Faisal Specialist Hospital and Research Center, this award reflects Novartis’ dedication to advancing high quality clinical research in Saudi Arabia and supporting local scientific capabilities.
Adding to this milestone, the Saudi Food and Drug Authority, in its 2025 clinical trials statistics, recognized Novartis as the top contributing multinational company to clinical trials in the Kingdom. This recognition is a testament to Novartis’ sustained investment in research and development and its commitment to bringing innovative treatments to patients in Saudi Arabia.
Together, these dual recognitions demonstrate how a strong clinical research ecosystem is transforming Saudi Arabia into a global healthcare innovation hub, directly supporting the ambitious goals of Saudi Vision 2030. By integrating innovative clinical trials with advanced research, Novartis contributes to ensuring that the Kingdom’s growing leadership in global healthcare innovation benefits patients locally, regionally and worldwide.
Amir Abdulaziz, country president, Novartis Saudi Arabia, said: “Starting the year with these two recognitions is a proud moment for all of us at Novartis Saudi Arabia and an inspiring reflection of our long-term partnership with the Kingdom. They highlight the strength of our collaboration with regulators, healthcare institutions and professionals, and our shared commitment to advancing clinical research that truly makes a difference for patients. In line with Vision 2030, we remain focused on reimagining medicine, investing in local talent and helping position Saudi Arabia as a leading global destination for healthcare innovation.”
Novartis has a long-standing presence in the Kingdom and is committed to supporting Vision 2030 by improving health outcomes, advancing innovation, contributing to economic diversification, and investing in people and communities. In 2025, Novartis medicines reached millions of patients across the Kingdom, providing access to innovative treatments in different therapeutics. By addressing unmet medical needs and bringing cutting-edge therapies to Saudi patients, Novartis helps improve the quality of life and long-term health outcomes.
People are at the core of Novartis’ impact in Saudi Arabia. In alignment with Vision 2030’s focus on employment, Saudization and women’s participation in the workforce, Novartis continues to attract, develop and retain local talent, foster an inclusive and diverse workplace, and support capability-building and leadership development. These efforts not only advance healthcare but also contribute to the growth of a vibrant life sciences sector and the broader economic transformation of the Kingdom.
